- Administer 18.5 MBq (0.5 mCi) of technetium Tc 99m tilmanocept at least 15 minutes prior to initiating intraoperative lymphatic mapping
- Recommended total injection is 0.1 mL in a single syringe; 0.5 mL in a single syringe or in multiple syringes (0.1 mL to 0.25 mL each); or 1 mL); or 1 mL administered in multiple syringes (0.2 mL to 0.5 mL each)
Note:
- In breast cancer administer through intradermal, subcutaneous, subareolar, and peritumoral injections
- In melanoma administer through intradermal or subcutaneous injections
- Radiolabeled technetium Tc 99m tilmanocept is to be used within 6 hours of its preparation
- Safety and effectiveness in pediatric patients have not been established
